论文部分内容阅读
在免疫系统中,负性共刺激分子可通过受体-配体的结合而抑制免疫应答,避免免疫造成的组织损伤,在维持自身免疫耐受方面发挥重要作用。负性共刺激分子也参与调节肿瘤的发生发展,细胞毒性T细胞相关抗原4(CTLA-4)和程序性死亡分子1(PD-1)主要表达于活化的T细胞,它们与相应配体结合后可传递抑制性信号,从而抑制机体的抗肿瘤免疫,导致肿瘤免疫逃逸的发生。在肿瘤患者中,利用特异性的抗体阻断这些负性共刺激分子,可消除它们的免疫抑制功能,从而促进机体的抗肿瘤免疫应答,实现对肿瘤生长的有效抑制。现针对负性共刺激分子的阻断抗体在肿瘤治疗中的研究进展进行综述。
In the immune system, negative costimulatory molecules can inhibit the immune response through the receptor-ligand binding to avoid immune damage caused by tissue plays an important role in the maintenance of autoimmune tolerance. Negative costimulatory molecules are also involved in the regulation of tumorigenesis. Cytotoxic T cell associated antigen 4 (CTLA-4) and programmed cell death molecule 1 (PD-1) are mainly expressed on activated T cells, which bind to the corresponding ligand After the transfer of inhibitory signals, thereby inhibiting the body’s anti-tumor immunity, leading to tumor immune escape occurred. In tumor patients, the use of specific antibodies to block these negative costimulatory molecules can eliminate their immunosuppressive function, thereby promoting the body’s anti-tumor immune response, to achieve effective inhibition of tumor growth. The research progress of blocking antibodies against negative costimulatory molecules in the treatment of cancer is reviewed.